{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T10:51:39Z","timestamp":1768474299291,"version":"3.49.0"},"reference-count":5,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["canadianjournalofophthalmology.ca","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Ophthalmology"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.jcjo.2023.07.008","type":"journal-article","created":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T16:10:35Z","timestamp":1691079035000},"page":"e251-e253","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["BRAF and MEK inhibitor-associated optic neuropathy in stage IIIC BRAF+ melanoma"],"prefix":"10.1016","volume":"58","author":[{"given":"Nicole V.","family":"Carrabba","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela Davila","family":"Siliezar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6049-0764","authenticated-orcid":false,"given":"Noor","family":"Laylani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4118-9690","authenticated-orcid":false,"given":"Andrew G.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcjo.2023.07.008_bib0001","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcjo.2023.07.008_bib0002","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1016\/j.ophtha.2021.05.008","article-title":"Ocular safety profile of BRAF and MEK inhibitors: data from the World Health Organization pharmacovigilance database","volume":"128","author":"Mettler","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2023.07.008_bib0003","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/14740338.2023.2189235","article-title":"Ocular adverse events associated with BRAF and MEK inhibitor combination therapy: a pharmacovigilance disproportionality analysis of the FDA Adverse Event Reporting System","volume":"2","author":"Huang","year":"2023","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jcjo.2023.07.008_bib0004","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/ICB.0000000000000585","article-title":"Bilateral visual field defects in a patient treated with the MEK and BRAF inhibitors trametinib and dabrafenib for melanoma of unknown origin","volume":"13","author":"Siedlecki","year":"2019","journal-title":"Retin Cases Brief Rep"},{"key":"10.1016\/j.jcjo.2023.07.008_bib0005","first-page":"e28372","article-title":"Retinal vein occlusion in a patient on dabrafenib and trametinib therapy for metastatic melanoma","volume":"14","author":"Molero-Senosiain","year":"2022","journal-title":"Cureus"}],"container-title":["Canadian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418223002338?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418223002338?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T20:11:49Z","timestamp":1757794309000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008418223002338"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":5,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S0008418223002338"],"URL":"https:\/\/doi.org\/10.1016\/j.jcjo.2023.07.008","relation":{},"ISSN":["0008-4182"],"issn-type":[{"value":"0008-4182","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BRAF and MEK inhibitor-associated optic neuropathy in stage IIIC BRAF+ melanoma","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcjo.2023.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}